Q1 EPS Estimates for Zimmer Biomet Lifted by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Stock analysts at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for Zimmer Biomet in a report issued on Thursday, April 3rd. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $2.12 per share for the quarter, up from their prior estimate of $2.11. The consensus estimate for Zimmer Biomet's current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet's FY2026 earnings at $8.80 EPS and Q1 2027 earnings at $2.25 EPS.

A number of other brokerages have also weighed in on ZBH. Royal Bank of Canada reduced their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Truist Financial restated a "hold" rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. JPMorgan Chase & Co. upgraded Zimmer Biomet from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. JMP Securities restated a "market outperform" rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Finally, Barclays decreased their target price on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of "Hold" and an average price target of $124.15.

Remove Ads

Zimmer Biomet Price Performance

ZBH stock traded up $0.04 during trading on Monday, hitting $102.30. The company had a trading volume of 2,275,065 shares, compared to its average volume of 1,629,112. The business has a 50 day moving average of $106.31 and a 200 day moving average of $107.04. The firm has a market capitalization of $20.36 billion, a price-to-earnings ratio of 22.99, a P/E/G ratio of 1.95 and a beta of 0.84. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet has a fifty-two week low of $97.69 and a fifty-two week high of $127.32.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the company posted $2.20 EPS.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.94%. Zimmer Biomet's dividend payout ratio is 21.57%.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.95% of the stock is owned by insiders.

Institutional Investors Weigh In On Zimmer Biomet

Institutional investors have recently modified their holdings of the stock. Stonebridge Financial Group LLC purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth $25,000. Dunhill Financial LLC increased its holdings in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock worth $26,000 after buying an additional 218 shares during the last quarter. Menard Financial Group LLC bought a new position in Zimmer Biomet during the fourth quarter valued at approximately $30,000. Accredited Wealth Management LLC acquired a new stake in Zimmer Biomet in the fourth quarter valued at approximately $36,000. Finally, Kentucky Trust Co bought a new stake in Zimmer Biomet in the fourth quarter worth approximately $39,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.